Overview

SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

Status:
Terminated
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pediatric Brain Tumor Consortium
Collaborator:
National Cancer Institute (NCI)
Treatments:
Semaxinib